[Retracted] Improved Cardiac Function and Attenuated Inflammatory Response by Additional Administration of Tirofiban during PCI for ST-Segment Elevation Myocardial Infarction Patients
Table 1
Baseline variables of the included STEMI patients by group.
PCI + tirofiban group
PCI group
Gender (male, n (%))
51 (82.26%)
49 (79.03%)
0.649
Age (years)
64.18 ± 3.84
65.19 ± 4.14
0.161
NYHA classification
0.480
Class I (%)
20 (32.26%)
23 (37.10%)
Class II (%)
29 (46.77%)
31 (50.00%)
Class III (%)
13 (20.97%)
8 (12.90%)
BMI (kg/m2)
24.74 ± 4.10
24.53 ± 4.21
0.779
Smoking history (%)
43 (69.35%)
45 (72.58%)
0.692
Hypertension (%)
52 (83.87%)
49 (79.03%)
0.488
Diabetes mellitus (%)
23 (37.10%)
20 (32.26%)
0.571
Onset time (h)
5.38 ± 1.69
5.51 ± 1.88
0.686
SBP (mmHg)
142.02 ± 26.12
140.49 ± 23.45
0.933
DBP (mmHg)
83.89 ± 15.73
82.59 ± 16.71
0.656
HR (time/min)
85.46 ± 20.43
87.29 ± 19.44
0.610
A total of 124 patients with STEMI were randomly assigned to PCI + tirofiban and PCI groups, 62 cases per groups. NYHA, New York Heart Association; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
